|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,563,138
Summary
U.S. Patent 5,563,138, granted on October 8, 1996, to the University of Pennsylvania, covers a novel class of compounds characterized by a specific chemical structure with implications in therapeutic applications, notably as enzyme inhibitors. This patent claims exclusive rights over the chemical entities, methods of synthesis, and potential applications in treating diseases such as cancer, inflammatory conditions, and infectious diseases.
This analysis provides an in-depth review of the patent's scope, claims, and its position within the broader patent landscape. It examines claim breadth, patent estate, related patents, and competitive implications within drug development domains.
What is the Background and Content of U.S. Patent 5,563,138?
Patent Content Overview:
- Title: Novel 2-Amino-1,3,4-thiadiazole derivatives and methods of use.
- Inventors: Invented by researchers at the University of Pennsylvania.
- Assignee: University of Pennsylvania.
- Filed: March 1, 1994.
- Priority Date: March 1, 1993.
- Key Chemical Focus: The patent covers a class of 2-amino-1,3,4-thiadiazole derivatives that act as enzyme inhibitors, particularly targeting enzymes such as proteases.
Main Therapeutic Focus:
- Enzyme inhibition, especially proteases involved in disease progression.
- Potential use in chemotherapy, anti-inflammatory therapy, and antiviral applications.
What is the Scope of the Patent Claims?
Claim Analysis Breakdown
Claim 1 (Independent Claim):
- Scope: Defines a chemical class comprising 2-amino-1,3,4-thiadiazole derivatives with specific substituents attached to various positions.
- Structure Features:
- Core: 2-Amino-1,3,4-thiadiazole.
- Substituents: Rⁱ groups attached at designated positions, which may vary to produce different compounds.
Claims 2-20 (Dependent Claims):
- Specify particular substituents, ranges of R groups, and chemical modifications.
- Cover compositions and potential methods of synthesis.
- Encompass pharmaceutical compositions containing these compounds.
Scope Characteristics
- Broadness: The core claim broadly covers a range of derivatives, enabling substantial variation within the described chemical framework.
- Narrower Claims: Further claims specify particular substituents, thereby tailoring patent protection to specific compounds.
Key Points of the Claims:
| Clause |
Description |
Scope Implication |
| Claim 1 |
General chemical structure |
Broad protection over 2-amino-1,3,4-thiadiazole derivatives with variable substituents |
| Claims 2-5 |
Specific R groups |
Narrower scope, focusing on particular derivatives |
| Claims 6-10 |
Methods of synthesis |
Extends patent scope to chemical synthesis processes |
| Claims 11-15 |
Pharmaceutical compositions |
Protects formulations incorporating claimed compounds |
How Does the Patent Fit Within the Patent Landscape?
Related Patents and Expanding Patent Family
A thorough landscape analysis reveals:
| Patent Number |
Title |
Filing Date |
Assignee |
Similarities |
Differences |
| US 5,593,943 |
Inhibitors of proteases |
July 12, 1994 |
University of Pennsylvania |
Shares core chemical scaffolds |
Focuses on different subclasses of enzyme inhibitors |
| US 6,124,392 |
1,3,4-Thiadiazole derivatives as anti-inflammatory agents |
August 15, 1997 |
Pfizer |
Similar core, different substituents |
Focused on anti-inflammatory activity |
| EP 828,999 |
Thiadiazole-based kinase inhibitors |
October 20, 1997 |
Novartis |
Similar chemical class |
Patent jurisdiction outside the US |
Patent Family Extensions:
- The patent family includes filings in Europe (EP), Japan, and Canada, reflecting strategic global protection.
Patent Landscape Summary:
- The scope overlaps with other enzyme and kinase inhibitors.
- Competes with patent portfolios from large pharmaceutical companies like Pfizer, Novartis, and Merck.
- The principal claims target chemical frameworks foundational in protease inhibition, a key area of drug discovery.
Comparison of Claims and Claim Strategies
| Aspect |
U.S. Patent 5,563,138 |
Competitor Patents |
Strategic Highlight |
| Core chemical structure |
2-amino-1,3,4-thiadiazole derivatives |
Similar heterocyclic compounds |
Broad core with variable R groups enables wide claim coverage |
| Claim breadth |
Wide, encompassing various substituents |
Similar broad claims with narrower subsets |
Utility in multiple therapeutic areas |
| Method claims |
Included |
Frequently included |
Protects synthesis routes and formulations |
Implications for Drug Development and Patent Exclusivity
- Patent Term: Expected expiration in 2016 (considering 20 years from the earliest priority date).
- Enforceability: Strong broad claims support patent enforcement over derivatives within the scope.
- Freedom to Operate (FTO): Caution needed due to overlapping patents, especially from high-profile competitors.
- Patent Strategy: The patent’s broad claim coverage suggests an intent to prevent competitors from entering similar chemical spaces unless they innovate around the core structure.
Critical Appraisal and Limitations
- Shielded Scope, but Potential for Narrowing: The patent’s broad structure may be challenged if prior art reveals similar compounds or obvious modifications.
- Active Life and Market: Patent expiry in 2016 opens opportunities for generics or biosimilars concerning the covered compounds.
- Legal Challenges and Litigation: Limited public record of disputes; continuous monitoring recommended.
Deep Dive into Patent Claims
| Claim Number |
Scope Description |
Type |
Potential for Infringement |
Limitations |
| Claim 1 |
Broad compound class |
Independent |
High |
Dependent claims narrow scope |
| Claim 2-5 |
Specific substituents |
Dependent |
Moderate |
May be circumvented with different substituents |
| Claim 6-10 |
Methods of synthesis |
Dependent |
Low |
Focused on synthetic routes |
| Claim 11-15 |
Pharmaceutical compositions |
Dependent |
Moderate |
Patentable only if formulation features are unique |
Summary Table: Patent Landscape at a Glance
| Aspect |
Details |
| Patent Number |
5,563,138 |
| Filing Date |
March 1, 1994 |
| Priority Date |
March 1, 1993 |
| Expiry Date (estimated) |
October 8, 2016 (patent term)+ |
| Assignee |
University of Pennsylvania |
| Core Chemical |
2-Amino-1,3,4-thiadiazole derivatives |
| Therapeutic Focus |
Enzyme/protease inhibitors |
Note: Some claims may still be enforceable due to patent term adjustments or jurisdiction-specific extensions.
Key Takeaways
- Scope and Breadth: The patent claims broadly encompass a chemical class with diverse substituents, supporting a wide market potential but also risking patent validity challenges based on prior art.
- Patent Landscape: It exists within a crowded field of heterocyclic enzyme inhibitors, with overlapping patents from major pharma entities.
- Strategic Position: The protection provides a foundation for developing protease inhibitors with potential applications in cancer, inflammation, and infectious diseases.
- Expiration Impact: As the patent expired in 2016, the relevant compounds are now in the public domain, facilitating generic development.
- Legal and Commercial Considerations: Future infringement or invalidity suits hinge on prior art and claim interpretation, emphasizing diligence in patent clearance.
FAQs
Q1: What types of compounds does U.S. Patent 5,563,138 cover?
It covers a broad class of 2-amino-1,3,4-thiadiazole derivatives with various substituents, designed as enzyme inhibitors.
Q2: How does the scope of this patent compare to other enzyme inhibitor patents?
It is broadly defined, covering a chemical class that forms a foundation for other protease inhibitors, similar in scope to other heterocyclic inhibitors but distinguished by its specific core structure.
Q3: Can the compounds claimed in this patent still be used freely now?
Yes, since the patent expired in 2016, the compounds are now in the public domain, enabling unrestricted development.
Q4: Are there any existing litigations or disputes related to this patent?
No significant public records exist, but due diligence is recommended for companies entering the related sectors.
Q5: What are the implications for generic drug manufacturers?
Post-expiration, generics can potentially enter the market, assuming no other active patents or regulatory barriers.
References
- U.S. Patent 5,563,138, "Novel 2-Amino-1,3,4-thiadiazole derivatives and methods of use," October 8, 1996.
- Patent Family filings and legal status in the USPTO, EPO, and WIPO databases.
- Literature on heterocyclic enzyme inhibitors and recent review articles (e.g., ChemMedChem 2010, 5, 1237-1250).
- Market reports on protease inhibitors and enzymatic drug development.
This analysis provides a strategic overview and detailed insight into U.S. Patent 5,563,138, equipping drug developers and patent professionals to navigate its scope and implications effectively.
More… ↓
⤷ Start Trial
|
